The primary pharmacology of ceftazidime/avibactam: in vitro translational biology
- 4 June 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 77 (9) , 2321-2340
Abstract
Previous reviews of ceftazidime/avibactam have focused on in vitro molecular enzymology and microbiology or the clinically associated properties of the combination. Here we take a different approach. We initiate a series of linked reviews that analyse research on the combination that built the primary pharmacology data required to support the clinical and business risk decisions to perform randomized controlled Phase 3 clinical trials, and the additional microbiological research that was added to the above, and the safety and chemical manufacturing and controls data, that constituted successful regulatory licensing applications for ceftazidime/avibactam in multiple countries, including the USA and the EU. The aim of the series is to provide both a source of reference for clinicians and microbiologists to be able to use ceftazidime/avibactam to its best advantage for patients, but also a case study of bringing a novel β-lactamase inhibitor (in combination with an established β-lactam) through the microbiological aspects of clinical development and regulatory applications, updated finally with a review of resistance occurring in patients under treatment. This first article reviews the biochemistry, structural biology and basic microbiology of the combination, showing that avibactam inhibits the great majority of serine-dependent β-lactamases in Enterobacterales and Pseudomonas aeruginosa to restore the in vitro antibacterial activity of ceftazidime. Translation to efficacy against infections in vivo is reviewed in the second co-published article, Nichols et al. (J Antimicrob Chemother 2022; dkac172).Keywords
This publication has 189 references indexed in Scilit:
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences, 2012
- NXL104 Irreversibly Inhibits the β-Lactamase from Mycobacterium tuberculosisBiochemistry, 2012
- OXA-163, an OXA-48-Related Class D β-Lactamase with Extended Activity Toward Expanded-Spectrum CephalosporinsAntimicrobial Agents and Chemotherapy, 2011
- Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2011
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase InhibitorAntimicrobial Agents and Chemotherapy, 2010
- Differential Selection of Single-Step AmpC or Efflux Mutants of Pseudomonas aeruginosa by Using Cefepime, Ceftazidime, or CeftobiproleAntimicrobial Agents and Chemotherapy, 2010
- Genetic Determinants Involved in the Susceptibility of Pseudomonas aeruginosa to β-Lactam AntibioticsAntimicrobial Agents and Chemotherapy, 2010
- Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological studyThe Lancet Infectious Diseases, 2010
- Diversity, Epidemiology, and Genetics of Class D β-LactamasesAntimicrobial Agents and Chemotherapy, 2010
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemasesJournal of Antimicrobial Chemotherapy, 2009